Academic Content and Language Evaluation of This Article
Citation of this article
Corresponding Author of This Article
Research Domain of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Number of Hits and Downloads for This Article
- Total Article Views (5537)
All Articles published online
|
Publishing Process of This Article
|
Aug 15, 2013 (publication date) through May 10, 2024
Times Cited of This Article
Journal Information of This Article
Publication Name
World Journal of Diabetes
ISSN
1948-9358
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
| For: | Kozlovski P, Foley J, Shao Q, Lukashevich V, Kothny W. Vildagliptin-insulin combination improves glycemic control in Asians with type 2 diabetes. World J Diabetes 2013; 4(4): 151-156 [PMID: 23961326 DOI: 10.4239/wjd.v4.i4.151] |
|---|---|
| URL: | https://www.wjgnet.com/1948-9358/full/v4/i4/151.htm |
| Number | Citing Articles |
| 1 |
Gillian M. Keating. Vildagliptin: A Review of Its Use in Type 2 Diabetes Mellitus. Drugs 2014; 74(5): 587 doi: 10.1007/s40265-014-0199-3
|
| 2 |
Ippei Kanazawa, Ken-ichiro Tanaka, Masakazu Notsu, Sayuri Tanaka, Nobuaki Kiyohara, Sayo Koike, Yuko Yamane, Yuko Tada, Motofumi Sasaki, Mika Yamauchi, Toshitsugu Sugimoto. Long-term efficacy and safety of vildagliptin add-on therapy in type 2 diabetes mellitus with insulin treatment. Diabetes Research and Clinical Practice 2017; 123: 9 doi: 10.1016/j.diabres.2016.11.010
|
| 3 |
Ibrahim El Ebrashy, Nabil El Kafrawy, Rana Raouf, Diana Yousry. Effectiveness, safety, and tolerability of vildagliptin or vildagliptin/metformin combination in patients with type 2 diabetes uncontrolled on insulin therapy in a real-world setting in Egypt: The OMEGA study. Diabetes Research and Clinical Practice 2020; 162: 108042 doi: 10.1016/j.diabres.2020.108042
|
| 4 |
Guang Ning, Weiqing Wang, Ling Li, Jianhua Ma, Xiaofeng Lv, Ming Yang, Wei Wang, Michael Woloschak, Valentina Lukashevich, Wolfgang Kothny. Vildagliptin as add‐on therapy to insulin improves glycemic control without increasing risk of hypoglycemia in Asian, predominantly Chinese, patients with type 2 diabetes mellitus. Journal of Diabetes 2016; 8(3): 345 doi: 10.1111/1753-0407.12303
|
| 5 |
Fu-Shun Yen, Jen-Huai Chiang, Chii-Min Hwu, Yu-Hsin Yen, Boniface J. Lin, James Cheng-Chung Wei, Chih-Cheng Hsu. All-cause mortality of insulin plus dipeptidyl peptidase-4 inhibitors in persons with type 2 diabetes. BMC Endocrine Disorders 2019; 19(1) doi: 10.1186/s12902-018-0330-7
|
| 6 |
Siri Malmgren, Bo Ahrén. DPP-4 inhibition contributes to the prevention of hypoglycaemia through a GIP–glucagon counterregulatory axis in mice. Diabetologia 2015; 58(5): 1091 doi: 10.1007/s00125-015-3518-7
|
| 7 |
Avivit Cahn, Roberto Miccoli, Angela Dardano, Stefano Del Prato. New forms of insulin and insulin therapies for the treatment of type 2 diabetes. The Lancet Diabetes & Endocrinology 2015; 3(8): 638 doi: 10.1016/S2213-8587(15)00097-2
|
| 8 |
P Panneerselvam, Dibakar Biswas, Hema Singh, K Dilip Kumar, P Ravi Kumar, Pramila Kalra, Santosh Revankar, Sona Warrier. Real-World Observational Study on Vildagliptin With Insulin (VIL-INS) or Vildagliptin and Metformin With Insulin (VIL-MET-INS) Therapy in Indian Patients With Type 2 Diabetes Mellitus. Cureus 2023; doi: 10.7759/cureus.47190
|
| 9 |
Takahisa Hirose, Manabu Suzuki, Isao Tsumiyama. Efficacy and Safety of Vildagliptin as an Add-on to Insulin with or without Metformin in Japanese Patients with Type 2 Diabetes Mellitus: A 12-week, Double-Blind, Randomized Study. Diabetes Therapy 2015; 6(4): 559 doi: 10.1007/s13300-015-0147-6
|
| 10 |
Helene Bihan, Winda L. Ng, Dianna J. Magliano, Jonathan E. Shaw. Predictors of efficacy of GLP-1 agonists and DPP-4 inhibitors: A systematic review. Diabetes Research and Clinical Practice 2016; 121: 27 doi: 10.1016/j.diabres.2016.08.011
|
| 11 |
D. Raccah. Basal insulin treatment intensification in patients with type 2 diabetes mellitus: A comprehensive systematic review of current options. Diabetes & Metabolism 2017; 43(2): 110 doi: 10.1016/j.diabet.2016.11.007
|
| 12 |
Yun-Zhao Tang, Gang Wang, Zhen-Huan Jiang, Tian-Tian Yan, Yi-Jun Chen, Min Yang, Ling-Ling Meng, Yan-Juan Zhu, Chen-Guang Li, Zhu Li, Ping Yu, Chang-Lin Ni. Efficacy and safety of vildagliptin, sitagliptin, and linagliptin as add-on therapy in Chinese patients with T2DM inadequately controlled with dual combination of insulin and traditional oral hypoglycemic agent. Diabetology & Metabolic Syndrome 2015; 7(1) doi: 10.1186/s13098-015-0087-3
|
| 13 |
Wayne H.-H. Sheu, Sung Woo Park, Yan Gong, Sabine Pinnetti, Sudipta Bhattacharya, Sanjay Patel, Thomas Seck, Hans-Juergen Woerle. Linagliptin improves glycemic control after 1 year as add-on therapy to basal insulin in Asian patients with type 2 diabetes mellitus. Current Medical Research and Opinion 2015; 31(3): 503 doi: 10.1185/03007995.2015.1010638
|